|
1
|
Mann JR, Kasthuri N, Raafat F, Pincott JR,
Parkes SE, Muir KR, Ingram LC and Cameron AH: Malignant hepatic
tumours in children: Incidence, clinical features and aetiology.
Paediatr Perinat Epidemiol. 4:276–289. 1990.
|
|
2
|
Zimmermann A: The emerging family of
hepatoblastoma tumours: From ontogenesis to oncogenesis. Eur J
Cancer. 41:1503–1514. 2005.
|
|
3
|
Eichenmüller M, Trippel F, Kreuder M, Beck
A, Schwarzmayr T, Häberle B, Cairo S, Leuschner I, von Schweinitz
D, Strom TM, et al: The genomic landscape of hepatoblastoma and
their progenies with HCC-like features. J Hepatol. 61:1312–1320.
2014.
|
|
4
|
Sumazin P, Chen Y, Treviño LR, Sarabia SF,
Hampton OA, Patel K, Mistretta TA, Zorman B, Thompson P, Heczey A,
et al: Genomic analysis of hepatoblastoma identifies distinct
molecular and prognostic subgroups. Hepatology. 65:104–121.
2017.
|
|
5
|
de La Coste A, Romagnolo B, Billuart P,
Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C,
Kahn A, et al: Somatic mutations of the beta-catenin gene are
frequent in mouse and human hepatocellular carcinomas. Proc Natl
Acad Sci USA. 95:8847–8851. 1998.
|
|
6
|
Taniguchi K, Roberts LR, Aderca IN, Dong
X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI,
et al: Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in
hepatocellular carcinomas and hepatoblastomas. Oncogene.
21:4863–4871. 2002.
|
|
7
|
Mokkapati S, Niopek K, Huang L, Cunniff
KJ, Ruteshouser EC, deCaestecker M, Finegold MJ and Huff V:
β-catenin activation in a novel liver progenitor cell type is
sufficient to cause hepatocellular carcinoma and hepatoblastoma.
Cancer Res. 74:4515–4525. 2014.
|
|
8
|
Buendia MA: Unravelling the genetics of
hepatoblastoma: Few mutations, what else? J Hepatol. 61:1202–1204.
2014.
|
|
9
|
Klijn C, Durinck S, Stawiski EW, Haverty
PM, Jiang Z, Liu H, Degenhardt J, Mayba O, Gnad F, Liu J, et al: A
comprehensive transcriptional portrait of human cancer cell lines.
Nat Biotechnol. 33:306–312. 2015.
|
|
10
|
Cairo S, Armengol C, De Reyniès A, Wei Y,
Thomas E, Renard CA, Goga A, Balakrishnan A, Semeraro M, Gresh L,
et al: Hepatic stem-like phenotype and interplay of
Wnt/beta-catenin and Myc signaling in aggressive childhood liver
cancer. Cancer Cell. 14:471–484. 2008.
|
|
11
|
Weber RG, Pietsch T, von Schweinitz D and
Lichter P: Characterization of genomic alterations in
hepatoblastomas. A role for gains on chromosomes 8q and 20 as
predictors of poor outcome. Am J Pathol. 157:571–578. 2000.
|
|
12
|
Vita M and Henriksson M: The Myc
oncoprotein as a therapeutic target for human cancer. Semin Cancer
Biol. 16:318–330. 2006.
|
|
13
|
Schwab M, Westermann F, Hero B and
Berthold F: Neuroblastoma: Biology and molecular and chromosomal
pathology. Lancet Oncol. 4:472–480. 2003.
|
|
14
|
Kretzner L, Blackwood EM and Eisenman RN:
Transcriptional activities of the Myc and Max proteins in mammalian
cells. Curr Top Microbiol Immunol. 182:435–443. 1992.
|
|
15
|
Kress TR, Sabò A and Amati B: MYC:
Connecting selective transcriptional control to global RNA
production. Nat Rev Cancer. 15:593–607. 2015.
|
|
16
|
Eichenmüller M, Gruner I, Hagl B, Häberle
B, Müller-Höcker J, von Schweinitz D and Kappler R: Blocking the
hedgehog pathway inhibits hepatoblastoma growth. Hepatology.
49:482–490. 2009.
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
18
|
Vadie N, Saayman S, Lenox A, Ackley A,
Clemson M, Burdach J, Hart J, Vogt PK and Morris KV: MYCNOS
functions as an antisense RNA regulating MYCN. RNA Biol.
12:893–899. 2015.
|
|
19
|
Baylin SB and Ohm JE: Epigenetic gene
silencing in cancer - a mechanism for early oncogenic pathway
addiction? Nat Rev Cancer. 6:107–116. 2006.
|
|
20
|
Brockmann M, Poon E, Berry T, Carstensen
A, Deubzer HE, Rycak L, Jamin Y, Thway K, Robinson SP, Roels F, et
al: Small molecule inhibitors of aurora-a induce proteasomal
degradation of N-myc in childhood neuroblastoma. Cancer Cell.
24:75–89. 2013.
|
|
21
|
Schnepp RW and Maris JM: Targeting MYCN: A
good BET for improving neuroblastoma therapy? Cancer Discov.
3:255–257. 2013.
|
|
22
|
Asteriti IA, Giubettini M, Lavia P and
Guarguaglini G: Aurora-A inactivation causes mitotic spindle pole
fragmentation by unbalancing microtubule-generated forces. Mol
Cancer. 10:1312011.
|
|
23
|
Hiyama E: Pediatric hepatoblastoma:
Diagnosis and treatment. Transl Pediatr. 3:293–299. 2014.
|
|
24
|
Sivaprakasam P, Gupta AA, Greenberg ML,
Capra M and Nathan PC: Survival and long-term outcomes in children
with hepatoblastoma treated with continuous infusion of cisplatin
and doxorubicin. J Pediatr Hematol Oncol. 33:e226–e230. 2011.
|
|
25
|
Lipshultz SE, Sambatakos P, Maguire M,
Karnik R, Ross SW, Franco VI and Miller TL: Cardiotoxicity and
cardioprotection in childhood cancer. Acta Haematol. 132:391–399.
2014.
|
|
26
|
Sehdev V, Peng D, Soutto M, Washington MK,
Revetta F, Ecsedy J, Zaika A, Rau TT, Schneider-Stock R, Belkhiri
A, et al: The aurora kinase A inhibitor MLN8237 enhances
cisplatin-induced cell death in esophageal adenocarcinoma cells.
Mol Cancer Ther. 11:763–774. 2012.
|
|
27
|
Zanellato I, Colangelo D and Osella D:
JQ1, a BET inhibitor, synergizes with cisplatin and induces
apoptosis in highly chemo-resistant malignant pleural mesothelioma
cells. Curr Cancer Drug Targets. 18:816–828. 2018.
|
|
28
|
Kalkat M, De Melo J, Hickman KA, Lourenco
C, Redel C, Resetca D, Tamachi A, Tu WB and Penn LZ: MYC
Deregulation in Primary Human Cancers. Genes (Basel). 8:82017.
|
|
29
|
Sala A: Editorial: Targeting MYCN in
Pediatric Cancers. Front Oncol. 4:3302015.
|
|
30
|
Rickman DS, Schulte JH and Eilers M: The
Expanding World of N-MYC-Driven Tumors. Cancer Discov. 8:150–163.
2018.
|
|
31
|
O’Brien EM, Selfe JL, Martins AS, Walters
ZS and Shipley JM: The long non-coding RNA MYCNOS-01 regulates MYCN
protein levels and affects growth of MYCN-amplified
rhabdo-myosarcoma and neuroblastoma cells. BMC Cancer.
18:2172018.
|
|
32
|
Beckers A, Van Peer G, Carter DR,
Gartlgruber M, Herrmann C, Agarwal S, Helsmoortel HH, Althoff K,
Molenaar JJ, Cheung BB, et al: MYCN-driven regulatory mechanisms
controlling LIN28B in neuroblastoma. Cancer Lett. 366:123–132.
2015.
|
|
33
|
Molenaar JJ, Domingo-Fernández R, Ebus ME,
Lindner S, Koster J, Drabek K, Mestdagh P, van Sluis P, Valentijn
LJ, van Nes J, et al: LIN28B induces neuroblastoma and enhances
MYCN levels via let-7 suppression. Nat Genet. 44:1199–1206.
2012.
|
|
34
|
Nguyen LH, Robinton DA, Seligson MT, Wu L,
Li L, Rakheja D, Comerford SA, Ramezani S, Sun X, Parikh MS, et al:
Lin28b is sufficient to drive liver cancer and necessary for its
maintenance in murine models. Cancer Cell. 26:248–261. 2014.
|
|
35
|
Nicolle D, Fabre M, Simon-Coma M, Gorse A,
Kappler R, Nonell L, Mallo M, Haidar H, Déas O, Mussini C, et al:
Patient-derived mouse xenografts from pediatric liver cancer
predict tumor recurrence and advise clinical management.
Hepatology. 64:1121–1135. 2016.
|
